Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Net Change in Cash

Last Annual Value

8.53M

3-Year CAGR

53%

5-Year CAGR

23%

10-Year CAGR

11%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Net Change in Cash

ANEB · NASDAQ
CompanyNet Change in Cash
CAGR 3Y
CAGR 5Y
CAGR 10Y
8.53M
N/A-12.8%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
-6.97M
N/AN/AN/A
76.25M
165.5%34.6%N/A
2.09M
N/A-19.8%N/A
-1.03M
N/AN/AN/A
-2.47M
N/AN/AN/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
-6.68M
N/AN/AN/A
14.08M
N/A-26.7%N/A
-8.47M
N/AN/AN/A
-14.54M
N/AN/AN/A
10.15M
-47.9%N/AN/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72